Therapeutic potential of α-glucosidase inhibitors to prevent postprandial endothelial dysfunction

International Heart Journal

Volumn 55, Issue 5, 2014, Pages 386-390

  Kato, Toru ^a   Node, Koichi ^b  

^a National Hospital Organization Tochigi Medical Center   (Japan)

^b Department of Cardiovascular and Renal Medicine ^*  (Japan)

Author keywords

Acarbose; Dipeptidyl peptidase (DPP) 4 inhibitor; Endothelial function; Glucagon like peptide 1 (GLP 1); Incretin; Miglitol; Type 2 Diabetes Mellitus (T2DM)

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENDOTHELIN 1; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; INSULIN; MEGLITINIDE; MIGLITOL; NATEGLINIDE; NITRIC OXIDE; PLACEBO; TRIACYLGLYCEROL; VALSARTAN; ALPHA GLUCOSIDASE; ENZYME INHIBITOR;

ARTICLE; ASIAN; ATHEROSCLEROSIS; CORONARY ARTERY DILATATION; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; POSTPRANDIAL HYPERGLYCEMIA; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); VASCULITIS; CARDIOVASCULAR DISEASE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PATHOPHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; HYPERGLYCEMIA; POSTPRANDIAL PERIOD; VASOCONSTRICTION;

EID: 84907525646     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.14-194     Document Type: Article

References (59)

1. Dinneen S, Gerich JE, Rizza R. Carbohydrate metabolism in noninsulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 707-13. (Review)
2. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22: 920-4.
3. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
4. Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 2000; 16: 125-32. (Review)
5. Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol 2009; 8: 23. (Review)
6. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-97. (Review)
7. Conaway DG, O'Keefe JH, Reid KJ, Spertus J. Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome. Am J Cardiol 2005; 96: 363-5.
8. Leiter LA, Ceriello A, Davidson JA, et al; International Prandial Glucose Regulation Study Group. Postprandial glucose regulation: new data and new implications. Clin Ther 2005; 27: S42-56. (Review)
9. Bonora E, Corrao G, Bagnardi V, et al. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 846-54.
10. Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006; 91: 813-9.
11. Hirata Y, Nagata D, Suzuki E, Nishimatsu H, Suzuki J, Nagai R. Diagnosis and treatment of endothelial dysfunction in cardiovascular disease. Int Heart J 2010; 51: 1-6. (Review)
12. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999; 34: 631-8. (Review)
13. Marfella R, Verrazzo G, Acampora R, et al. Glutathione reverses systemic hemodynamic changes by acute hyperglycemia in healthy subjects. Am J Physiol 1995; 268: E1167-73.
14. Kawano H, Motoyama T, Hirashima O, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999; 34: 146-54.
15. Shige H, Ishikawa T, Suzukawa M, et al. Endothelium-dependent flow-mediated vasodilation in the postprandial state in type 2 diabetes mellitus. Am J Cardiol 1999; 84: 1272-4.
16. Giugliano D, Marfella R, Coppola L, et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997; 95: 1783-90.
17. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008; 57: 1349-54.
18. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100: 2153-7. (Review)
19. Ihnat MA, Kaltreider RC, Thorpe JE, et al. Attenuated superoxide dismutase induction in retinal cells in response to intermittent high versus continuous high glucose. Am J Biochem Biotech 2007; 3: 16-23.
20. Meugnier E, Faraj M, Rome S, et al. Acute hyperglycemia induces a global downregulation of gene expression in adipose tissue and skeletal muscle of healthy subjects. Diabetes 2007; 56: 992-9.
21. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-6.
22. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-94.
23. Mari A, Gastaldelli A, Foley JE, Pratley RE, Ferrannini E. Betacell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide. Diabetes Care 2005; 28: 1132-8.
24. Ai M, Tanaka A, Ogita K, Shimokado K. Favorable effects of early insulin secretion by nateglinide on postprandial hyperlipidemia in patients with type 2 diabetes. Diabetes Care 2006; 29: 1180.
25. Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006; 91: 837-42.
26. Shimabukuro M, Higa N, Takasu N, Tagawa T, Ueda S. A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients. Diabet Med 2004; 21: 983-6.
27. Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol 2010; 9:12.
28. Tomiyama H, Kohro T, Higashi Y, et al. A multicenter study design to assess the clinical usefulness of semi-automatic measurement of flow-mediated vasodilatation of the brachial artery. Int Heart J 2012; 53: 170-5.
29. Inoue T, Matsuoka H, Higashi Y, et al. Flow-mediated vasodilation as a diagnostic modality for vascular failure. Hypertens Res 2008; 31: 2105-13. (Review)
30. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65.
31. NAVIGATOR Study Group, Holman RR, Haffner SM, McMurray JJ, et al. Effects of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1463-76.
32. Sawada T, Shiotani H, Terashita D, et al. Comparison of effects of α-Glucosidase inhibitors and glinide drugs on endothelial dysfunction in diabetic patients with coronary artery disease. Circ J 2014; 78: 248-55.
33. Maruyama C, Imamura K, Teramoto T. Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb 2003; 10: 186-91.
34. Karabulut A, Iltumur K, Toprak N, et al. Insulin response to oral glucose loading and coronary artery disease in nondiabetics. Int Heart J 2005; 46: 761-70.
35. Arcaro G, Cretti A, Balzano S, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002; 105: 576-82.
36. Cardillo C, Nambi SS, Kilcoyne CM, et al. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation 1999; 100: 820-5.
37. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun 2000; 269: 713-7.
38. Kashiwagi A, Shinozaki K, Nishio Y, et al. Endothelium-specific activation of NAD(P)H oxidase in aortas of exogenously hyperinsulinemic rats. Am J Physiol 1999; 277: E976-83.
39. Zhu Q, Tong Y, Wu T, Li J, Tong N. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis. Clin Ther 2013; 35: 880-99.
40. Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2014 (in press)
41. Li C, Hung YJ, Qamruddin K, Aziz MF, Stein H, Schmidt B. International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011; 92: 57-64.
42. Schnell O, Mertes G, Standl E. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy. Diabetes Obes Metab 2007; 9: 853-8.
43. Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008; 25: 435-41.
44. Schnell O, Sheu WH, Watada H, Kalra S, Yamamoto N. An alphaglucosidase inhibitor, acarbose, reduces body weight irrespective of glycemic control status. Diabetes 2013; 62: A553.
45. Nakhaee A, Sanjari M. Evaluation of effect of acarbose consumption on weight losing in non-diabetic overweight or obese patients in Kerman. J Res Med Sci 2013; 18: 391-4.
46. Standl E, Theodorakis MJ, Erbach M, Schnell O, Tuomilehto J. On the potential of acarbose to reduce cardiovascular disease. Cardiovasc Diabetol 2014; 13: 81.
47. Aoki K, Kamiyama H, Yoshimura K, Shibuya M, Masuda K, Terauchi Y. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. Acta Diabetol 2012; 49: 225-30.
48. Narita T, Yokoyama H, Yamashita R, et al. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab 2012; 14: 283-7.
49. Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995; 30: 892-6.
50. Yabe D, Watanabe K, Sugawara K, et al. Effects of sitagliptin, acarbose and sulfonylureas on postprandial levels of GLP-1 and GIP in Japanese patients with type 2 diabetes. Diabetologia 2011; 54: S342.
51. Zheng MY, Yang JH, Shan CY, et al. Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovasc Diabetol 2013; 12: 73.
52. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011; 54: 10-8. (Review)
53. Holst JJ, Knop FK, Vilsbøll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 2011; 34: S251-7. (Review)
54. Kusunoki Y, Katsuno T, Myojin M, et al. Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. Endocr J 2013; 60: 431-9.
55. Theodorakis MJ, Carlson O, Michopoulos S, et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 2006; 290: E550-9.
56. Hiki M, Shimada K, Kiyanagi T, et al. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease-Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (JMACH)-. Circ J 2010; 74: 1471-8.
57. Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs 2000; 59: 521-49. (Review)
58. Ahr HJ, Boberg M, Brendel E, Krause HP, Steinke W. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Arzneimittelforschung 1997; 47: 734-45.
59. Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E1209-15.